Adamas Pharmaceuticals Inc (ADMS) Stock Analyst Ratings
USA - NASDAQ:ADMS - Common Stock
8.22
+0.06 (+0.74%)
8.3
+0.08 (+0.97%)
ChartMill assigns a Buy % Consensus number of 71% to ADMS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 8.69. This target is 5.72% above the current price.
ADMS was analyzed by 14 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about ADMS.
In the previous month the buy percentage consensus was at a similar level.
ADMS was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2021-11-17 | Northland Capital Markets | Downgrade | Outperform -> Market Perform |
| 2021-10-12 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2021-10-12 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2021-10-12 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2021-10-11 | William Blair | Downgrade | Outperform -> Market Perform |
| 2021-06-07 | HC Wainwright & Co. | Maintains | Buy |
Adamas Pharmaceuticals Inc / ADMS FAQ
Can you provide the average price target for Adamas Pharmaceuticals Inc stock?
14 analysts have analysed ADMS and the average price target is 8.69 null. This implies a price increase of 5.72% is expected in the next year compared to the current price of 8.22.
What is the consensus rating for Adamas Pharmaceuticals Inc (ADMS) stock?
The consensus rating for Adamas Pharmaceuticals Inc (ADMS) is 71.4286 / 100 . This indicates that analysts generally have a positive outlook on the stock.